Zacks Research Issues Positive Outlook for CORT Earnings

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at Zacks Research boosted their Q1 2025 earnings estimates for Corcept Therapeutics in a research report issued to clients and investors on Wednesday, January 29th. Zacks Research analyst K. Das now expects that the biotechnology company will earn $0.29 per share for the quarter, up from their previous forecast of $0.27. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q1 2026 earnings at $0.48 EPS, Q3 2026 earnings at $0.75 EPS and FY2026 earnings at $2.53 EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.14. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company had revenue of $182.55 million during the quarter, compared to the consensus estimate of $171.97 million. During the same quarter in the prior year, the company posted $0.28 EPS. The firm’s revenue was up 47.7% on a year-over-year basis.

CORT has been the subject of a number of other reports. Sandler O’Neill restated a “buy” rating on shares of Corcept Therapeutics in a research note on Friday, October 18th. Canaccord Genuity Group upped their price target on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a “buy” rating in a report on Thursday. StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Monday, November 25th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price target on shares of Corcept Therapeutics in a research report on Thursday, October 31st. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $88.25.

Corcept Therapeutics Stock Down 4.3 %

CORT opened at $66.92 on Friday. The firm has a market cap of $7.01 billion, a P/E ratio of 53.11 and a beta of 0.56. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.70. The business has a 50 day moving average price of $56.02 and a 200 day moving average price of $46.91. Corcept Therapeutics has a twelve month low of $20.84 and a twelve month high of $71.29.

Institutional Investors Weigh In On Corcept Therapeutics

Large investors have recently modified their holdings of the stock. Hancock Whitney Corp boosted its stake in Corcept Therapeutics by 1.2% in the 3rd quarter. Hancock Whitney Corp now owns 22,954 shares of the biotechnology company’s stock valued at $1,062,000 after buying an additional 270 shares in the last quarter. Principal Securities Inc. lifted its holdings in shares of Corcept Therapeutics by 63.6% during the fourth quarter. Principal Securities Inc. now owns 1,243 shares of the biotechnology company’s stock valued at $63,000 after acquiring an additional 483 shares during the period. KBC Group NV boosted its stake in shares of Corcept Therapeutics by 21.3% in the 3rd quarter. KBC Group NV now owns 2,822 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 496 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Corcept Therapeutics by 20.3% in the 4th quarter. GAMMA Investing LLC now owns 2,996 shares of the biotechnology company’s stock worth $151,000 after purchasing an additional 506 shares during the last quarter. Finally, Kestra Investment Management LLC acquired a new stake in shares of Corcept Therapeutics during the 4th quarter worth about $27,000. 93.61% of the stock is currently owned by institutional investors.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 3,394 shares of the business’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $48.97, for a total value of $166,204.18. Following the sale, the insider now owns 5,796 shares of the company’s stock, valued at $283,830.12. The trade was a 36.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $59.88, for a total transaction of $131,736.00. The disclosure for this sale can be found here. Insiders have sold 31,405 shares of company stock worth $1,627,772 over the last three months. Company insiders own 20.50% of the company’s stock.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.